Paget's disease

Active Ingredient: Calcitonin

Indication for Calcitonin

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

For the treatment of Paget’s disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment.

For this indication, competent medicine agencies globally authorize below treatments:

100 IU daily


Dosage regimens

Regimen A: Intramuscular, 100 international units calcitonin, once daily.

Regimen B: Intramuscular, 50 international units calcitonin, 3 times weekly.

Regimen C: Subcutaneous, 100 international units calcitonin, once daily.

Regimen D: Subcutaneous, 50 international units calcitonin, 3 times weekly.

Detailed description

The recommended dosage is 100 IU per day, however, a minimum dosage regimen of 50 IU three times a week has achieved clinical and biochemical improvement. Dosage is to be adjusted to the individual patient’s needs.

Treatment should be discontinued once the patient has responded and symptoms have resolved. Duration of treatment should not normally exceed 3 months due to evidence of an increased risk of malignancies with long term calcitonin use. Under exceptional circumstances, e.g. in patients with impending pathologic fracture, treatment duration may be extended up to a recommended maximum of 6 months. Periodic re-treatment may be considered in these patients, and should take into account the potential benefits and evidence of an increased risk of malignancies and long term calcitonin use. The effect of calcitonin may be monitored by measurement of suitable markers of bone remodeling, such as serum alkaline phosphatase or urinary hydroxyproline or deoxypyridinoline. The dose may be reduced after the condition of the patient has improved.

200-400 IU in 2 divided doses daily


Dosage regimens

Nasal, between 100 international units calcitonin and 200 international units calcitonin, 2 times daily.

Active ingredient


Calcitonin is a calciotropic hormone, which inhibits bone resorption by a direct action on osteoclasts. By inhibiting osteoclast activity via its specific receptors, salmon calcitonin decreases bone resorption.

Read more about Calcitonin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.